These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22017171)

  • 1. Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature.
    Fonollosa A; Artaraz J; Les I; Martinez-Berriotxoa A; Izquierdo JP; Lopez AS; Gardeazaba J; Berasategui B; Martinez-Alday N
    Ocul Immunol Inflamm; 2012 Feb; 20(1):44-8. PubMed ID: 22017171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review.
    Massara A; Cavazzini L; La Corte R; Trotta F
    Semin Arthritis Rheum; 2010 Feb; 39(4):313-9. PubMed ID: 19147181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcoid-related uveitis occurring during adalimumab therapy.
    Seve P; Varron L; Broussolle C; Denis P; Kodjikian L
    Ocul Immunol Inflamm; 2012 Feb; 20(1):59-60. PubMed ID: 22017197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarcoid-related uveitis occurring during etanercept therapy.
    Hashkes PJ; Shajrawi I
    Clin Exp Rheumatol; 2003; 21(5):645-6. PubMed ID: 14611117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists.
    Lamrock E; Brown P
    Australas J Dermatol; 2012 Nov; 53(4):e87-90. PubMed ID: 23157794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
    Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
    Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis].
    Haake H; Köneke J; Amann K; vom Dahl J; Janssen U
    Med Klin (Munich); 2007 Oct; 102(10):852-7. PubMed ID: 17928969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
    Clementine RR; Lyman J; Zakem J; Mallepalli J; Lindsey S; Quinet R
    J Clin Rheumatol; 2010 Sep; 16(6):274-9. PubMed ID: 20808167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary sarcoidosis associated with etanercept therapy.
    Farah RE; Shay MD
    Pharmacotherapy; 2007 Oct; 27(10):1446-8. PubMed ID: 17896899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents.
    Saurenmann RK; Levin AV; Feldman BM; Laxer RM; Schneider R; Silverman ED
    J Pediatr; 2006 Dec; 149(6):833-6. PubMed ID: 17137902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
    Paul C; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
    [No Abstract]   [Full Text] [Related]  

  • 12. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
    Kakkassery V; Mergler S; Pleyer U
    Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature.
    Taban M; Dupps WJ; Mandell B; Perez VL
    Ocul Immunol Inflamm; 2006 Jun; 14(3):145-50. PubMed ID: 16766397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists.
    Gottlieb GS; Lesser CF; Holmes KK; Wald A
    Clin Infect Dis; 2003 Sep; 37(6):838-40. PubMed ID: 12955647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept: An overview.
    Goffe B; Cather JC
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S105-11. PubMed ID: 12894133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcoidosis as an adverse effect of tumor necrosis factor inhibitors.
    Cathcart S; Sami N; Elewski B
    J Drugs Dermatol; 2012 May; 11(5):609-12. PubMed ID: 22527429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
    Braun J; Baraliakos X; Listing J; Sieper J
    Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication.
    Tong D; Manolios N; Howe G; Spencer D
    Intern Med J; 2012 Jan; 42(1):89-94. PubMed ID: 22389903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab.
    Dragnev D; Barr D; Kulshrestha M; Shanmugalingam S
    BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24005973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.